If the data for any of the programs are good, I wouldn't be surprised if they partnered up with another biotech/pharma company looking to expand their portfolio to the CAR-T, CAR-NK space and are willing to pay an upfront free with milestone payments as it moves through development.
This would be an ideal de-risking - yes we lose the potential profits that may be generated, but at an early stage, this would provide confidence in the programs that are invested on.
I don't think the team will agree to a buyout and I don't think pharma will be focused on a buyout as CHM has multiple programs and does not work from a platform technology to generate their programs.
If the data for any of the programs are good, I wouldn't be...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $21.93K | 1.168M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1519165 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1262067 | 4 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |